SILO PHARMA, INC. Development Costs, Period Cost
SILO PHARMA, INC. (SILO) reported Development Costs, Period Cost of $13.65 thousand for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DevelopmentCosts · last filed 2021-08-13
- SILO PHARMA, INC. development costs, period cost for the quarter ending 2021-06-30 was $13.65K, a 945.18% increase year-over-year.
- SILO PHARMA, INC. development costs, period cost for the quarter ending 2021-03-31 was $19.39K, a 44.64% decline year-over-year.
- SILO PHARMA, INC. development costs, period cost for the quarter ending 2020-12-31 was $8.86K.
- SILO PHARMA, INC. development costs, period cost for the quarter ending 2020-09-30 was $17.36K.
- SILO PHARMA, INC. development costs, period cost for fiscal 2020 was $62.55K, a 1.44% decline from fiscal 2019.
- SILO PHARMA, INC. development costs, period cost for fiscal 2019 was $63.47K.
| Period end | Development Costs, Period Cost 3 month | Development Costs, Period Cost 6 month | Development Costs, Period Cost 9 month | Development Costs, Period Cost 12 month |
|---|---|---|---|---|
| 2021-06-30 | $13.65K 10-Q · filed 2021-08-13 | $33.04K 10-Q · filed 2021-08-13 | $41.90K derived: sum of 3 quarters · filed 2021-08-13 | $59.26K derived: sum of 4 quarters · filed 2021-08-13 |
| 2021-03-31 | $19.39K 10-Q · filed 2021-05-17 | $28.25K derived: sum of 2 quarters · filed 2021-05-17 | $45.61K derived: sum of 3 quarters · filed 2021-05-17 | $46.92K derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-12-31 | $8.86K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-17 | $26.23K derived: sum of 2 quarters · filed 2021-05-17 | $27.53K derived: sum of 3 quarters · filed 2021-08-13 | $62.55K 10-K/A · filed 2021-05-17 |
| 2020-09-30 | $17.36K 10-Q · filed 2020-11-05 | $18.67K derived: sum of 2 quarters · filed 2021-08-13 | $53.69K 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $1.31K 10-Q · filed 2021-08-13 | $36.33K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $35.02K 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $63.47K 10-K/A · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |